Duo Oncology is a pioneering startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company's primary focus is on the development of innovative nanomedicines for cancer patients. These nanomedicines are designed to be tumor responsive, meaning they are engineered to directly target and deliver drug payloads to the tumor, even those surrounded by obstructive stromal tissue. This approach aims to enhance the effectiveness of cancer treatment while minimizing potential side effects.

The company's team comprises practicing clinical oncologists and pharmaceutical scientists from around the globe. This diverse team is tasked with guiding the nanomedicines through the complex drug approval process, ensuring they reach patients as quickly as possible.

Duo Oncology's business model revolves around the development, approval, and commercialization of these nanomedicines. The company generates revenue through the sales of these innovative treatments to healthcare providers who serve cancer patients.

The company's proprietary chemistry uses principles from the self-assembly of DNA to pack drugs into particles that are ten times smaller than those of competing products. This unique approach allows Duo Oncology to customize its particle platform into powerful combination therapies for patients with stroma-rich tumors, potentially offering a new and more effective treatment option for this patient group.

Keywords: Duo Oncology, cancer treatment, nanomedicines, tumor responsive, drug approval process, pharmaceutical scientists, clinical oncologists, proprietary chemistry, combination therapies, stroma-rich tumors.